3 Top Dow Jones Dividend Stocks to Buy for Passive Income in 2026

Verizon's U.S. wireless business is running up against a saturated market with roughly 2% year-over-year revenue growth last quarter, constraining capital-appreciation prospects while supporting a forward dividend yield near 6.1%. Merck, where Keytruda represents about half of sales and faces patent cliffs beginning in 2028, has executed large acquisitions — Prometheus ($10.8B, 2023), Verona Pharma (~$10B, Oct), and Cidara (~$9.2B) — and forecasts these moves to drive roughly $70B of new revenue by the mid-2030s, with a current dividend yield around 2.9%. Coca-Cola remains a stable cash generator with a forward yield near 2.7% and 63 consecutive years of dividend increases, supported by strong brand loyalty.

Analysis

Market structure: Defensive dividend names (VZ 6.1% forward yield, KO 2.7%) win in a risk-off, high-rate regime as yield-seeking flows substitute for lower-grade bonds. Merck (MRK) is a long-term growth takeover story—$30B+ of M&A since 2023 and guidance for ~$70B incremental revenue by mid-2030s—but revenue realization depends on approvals and commercialization timelines (2028+). Cross-assets: higher payers compress IG bond demand and lift dividend stocks; expect modest fall in equity vol for Staples, slight FX USD strength on risk-off; commodities unaffected.

Risk assessment: Tail risks include MRK clinical/approval failures or patent litigation around Keytruda (patent cliff 2028) and an unexpected VZ dividend cut if FCF declines >200bps. Near-term (days-weeks) risks: earnings beats/misses and ex-dividend mechanics; medium-term (6–18 months): M&A integration and trial readouts; long-term (3–10 years): MRK revenue realization and wireless ARPU secular trend. Hidden dependency: MRK’s $70B assumes favorable market access and minimal pricing pressure.

Trade implications: Income-focused trades: buy VZ as a 2–3% portfolio position for yield with a hedge (buy 3–6 month puts 3–5% OTM) or sell cash-secured puts 6–8% OTM to lower basis. Growth/bisect: establish a 3–4% core MRK position for a 3–5 year horizon and add 1.5% long-dated (Jan 2028) LEAPS calls to lever optionality on pipeline upside. Defensive rotation: shift 2% from XLY into KO, add covered-call overlays to boost yield by ~2–3% annualized.

Contrarian angles: Market underprices MRK integration risk—don’t pay full multiple today for $70B optionality unless trial milestones are met; AT&T’s dividend history is a precedent that telecom yields can be compressed into cuts if capex rises. Conversely, KO’s global pricing power and brand loyalty are under-owned; a sustained organic growth >3% in next 4 quarters would justify re-rating. Key monitors: VZ FCF/dividend ratio (alert if <1.1), MRK pivotal trial calendar (next 12–36 months), KO organic revenue trends quarterly.

Key Decisions for Investors

• Consider establishing a 2–3% long position in VZ for income; sell cash-secured puts 6–8% OTM (1–3 month tenors) to enhance yield and set a hard sell/stop if FCF-to-dividend ratio falls below 1.1 or yield spikes >750bps from current level.
• Initiate a 3–4% core long position in MRK with a 3–5 year horizon to capture acquisition-driven revenue; complement with a 1.5% notional purchase of Jan‑2028 LEAPS calls to retain upside while limiting cash outlay—trim/reevaluate on any pivotal trial failure or missed 12‑month milestones.
• Reallocate 2% from consumer discretionary (e.g., XLY) into KO as a defensive compounder; sell 3–6 month covered calls ~3–5% OTM to boost annualized yield by ~2–3% and add on any >3% pullback from current levels.
• Hedge telecom income exposure: buy 3–6 month VZ puts 3–5% OTM (cost cap ~1–2% of position) or maintain cash-secured put sells as an entry strategy; monitor for dividend coverage <1.0 or major capex guidance revision as exit triggers.